Pliant Therapeutics, Inc.
PLRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Pliant Therapeutics, Inc. focuses on Biotechnology services and products. Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. At a $53.5M market cap, Pliant Therapeutics, Inc. ranks as a micro-cap company within healthcare. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
Market Cap
$53.5M
Beta
1.28
P/E (TTM)
—
P/E (Fwd)
-0.67
EPS (TTM)
$-1.49
EPS (Fwd)
$-1.28
ROE
-50.3%
ROA
-23.3%
Cash
$158.1M
Total Debt
$28.7M
Free CF
-$42.5M
52W Change
-52.3%
Annual Financials
Cash vs Debt
Where PLRX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PLRX finished 21.74% below its 150-day moving average ($1.15) and 23.73% below its 200-day moving average ($1.18). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PLRX overbought or oversold?
At the October 20, 2026 close, PLRX's RSI(14) was 28.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $158.1M in cash and $28.7M in debt, PLRX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$42.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -50.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $9.7M (2022) to $0 (2025), a 100% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing PLRX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.